Open Menu
Meetings & Education
Meetings & Education
Research & Data
Practice & Patients
Career Development
News & Initiatives
Get Involved
IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The B3 Thymomas and Thymic Carcinomas Cohort.
Background:
In patients with rare cancers, there is an unmet medical need for investigating innovative therapeutics. Indeed, these diseases are rarely assessed in clinical trials. Thymic epithelial tumors (TET) are rare heterogeneous thoracic malignancies. B3 TET and thymic carcinomas are more aggressive and prone to metastatic spreading. The standard 1st line treatment relies on platinum-based chemotherapy. Consensual 2nd line treatment has not been identified yet. Several studies showed limited efficacy of PD-1 blockade in B3 TET and thymic carcinomas. Concurrent blockage of TIGIT and PD-1 immune checkpoint B3 TET may improve outcomes according to translational studies.
Methods:
IMMUNORARE5 (NCT06790706) is a platform of 5 single arm phase II trials testing the safety and efficacy of Domvanalimab (anti-TIGIT) and Zimberelimab (anti PD-1) in 5 independent cohorts of rare cancers. The trial, sponsored by Lyon University Hospital, is conducted in 15 French centers, in partnership with the corresponding French national reference centers.
The B3 TET and thymic carcinomas cohort, led in collaboration with the RYTHMIC Network (www.rythmic.org), will enroll 26 patients after failure of at least one line of platinum-based chemotherapy, with evaluable lesions at baseline according to RECIST criteria. Patients previously treated with immunotherapy are not eligible. Patients will receive Domvanalimab and Zimberelimab intra-venous, every three weeks, until disease progression or unacceptable toxicity.
The primary endpoint is the progression-free survival rate at 6 months. The secondary endpoints are overall response rate and duration of the response, progression-free survival, overall survival and tolerability.
The trial is designed with a two-stage Simon design, with early termination for futility (5% one-sided alpha level, 80% power). The treatment would be considered interesting if the percentage of patients free from disease progression at 6-months is statistically higher than 40%; 65% is expected.
Translational research projects will be developed aiming at deciphering cellular and molecular mechanisms involved in response to treatment.
Moreover, data from the prospective database of the RYTHMIC network will be investigated to build a synthetic historical arm representative of the efficacy of the standard treatments in a similar population of patients.
Disclaimer
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Author Details
Michaël Duruisseaux
Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon (INSERM 1052, CNRS 5286), Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France
Authors chevron_right
Associated Organizations chevron_right
Abstract Details
Meeting
2025 ASCO Annual Meeting
Session Type
Poster Session
Session Title
Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
View MoreAbstract Disclosure
open_in_new
Similar Abstracts
text_snippet
Abstract
2023 ASCO Annual Meeting
First Author: Meredith McAdams
text_snippet
Abstract
2023 ASCO Genitourinary Cancers Symposium
First Author: Ignacio Duran
text_snippet
Abstract
2023 ASCO Annual Meeting
First Author: Christos Chouaid
text_snippet
Abstract
2023 ASCO Annual Meeting
First Author: Samuel J Klempner
Download
Your Privacy
ASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us.
Because we respect your right to privacy, you can choose not to allow some or all types of cookies. Click on the different category headings to find out more about the types of cookies used on our websites and change your default settings to match your preferences. Please read these carefully. Blocking some types of cookies may impact your experience on the site, including our ability to personalize the content you receive from us.
For a full explanation of the personal and non-personal information we collect on our site, including how we use that information and your rights regarding that information, please review our Privacy Policy. Use of our website is also subject to our Terms of Use.
Allow All
Manage Consent Preferences
Essential Website Cookies
Always Active
These cookies are necessary for the website to function and are sometimes referred to as “strictly necessary” cookies. They make sure the website delivers you information and services in an optimal way.
They are often set in response to an action you take, such as changing your cookie preferences, setting your privacy preferences, logging in to our website, asking the site to remember you on subsequent pages, or filling in forms. These cookies do not identify you personally.
You can set your browser to block or alert you about all cookies, including essential website cookies, but some parts of the site will not work as a result.
Cookies Details‎
Performance and Functionality Cookies
Performance and Functionality Cookies
These cookies enhance the performance and functionality of our websites and the services we provide. For example, these cookies can keep track of your visitor session in between visits, enable you to share content through social media, use embedded media players, and use comment features. They also help us balance website load and improve site speed and performance.
All information these cookies collect is aggregated and therefore anonymous. These cookies may be set by us or by third party providers whose services we have added to our websites. These cookies are non-essential, but without these cookies, certain functionality or enhanced features may become unavailable.
Cookies Details‎
Personalization and Analytics Cookies
Personalization and Analytics Cookies
These cookies collect information that is used to help us understand how our websites and content are used, help us customize our websites and application for you in order to enhance your experience, and help us improve the content that ASCO creates to better meet our members’ and visitors’ needs. Examples include cookies that show us which content might be most popular with our visitors, understand browsing history of our users, understand the effectiveness of our own advertising, and enable us to recommend content to individual users based on their profile and activities on the website.
These cookies may be set by us or by third party providers whose services we have added to our websites.
These cookies are non-essential to the functionality of the site and may contain information that enables us or our third party providers to identify you and build a profile of your interests. Without these cookies, you will not be able to have a customized or personalized experience within our website.
Cookies Details‎
Advertising Cookies and Social Media Cookies
Advertising Cookies and Social Media Cookies
Advertising (or Targeting) cookies are third party cookies that may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant ads on other sites.
Social Media Cookies are cookies set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your activities across other sites and building a profile of your interests. This may impact the content and messages you see on other websites you visit.
These cookies and the data collected by the third parties may be combined with data from other users or data about your activity on other sites. While the data collected on our site is aggregate or non-personal, the data may be used by such third parties to link you on other platforms or otherwise identify you.
If you do not allow these cookies, you may experience less targeted advertising.
Cookies Details‎
Back Button
Cookie List
Search Icon
Filter Icon
Clear
checkbox labellabel
ApplyCancel
ConsentLeg.Interest
checkbox labellabel
checkbox labellabel
checkbox labellabel
View Cookies
Name
cookie name
Save Settings
